Your heart muscle is held together by molecular anchors called desmosomes¹¹ desmosomes
protein complexes at the intercalated discs between cardiomyocytes — they transmit mechanical force and maintain cell-cell adhesion during every heartbeat. Desmoplakin (DSP) is the largest desmosomal protein and acts as the structural linchpin, connecting desmosomal cadherins at the cell surface to the intermediate filament cytoskeleton deep inside the cell. Without functional desmoplakin, cardiac cells cannot hold together under the mechanical stress of beating, leading to cell death, fibrofatty replacement of the myocardium, and the substrate for life-threatening arrhythmias.

The p.Arg160Ter mutation (c.478C>T, NM_004415.4) converts arginine at position 160 into a premature stop codon. The resulting truncated mRNA is targeted for nonsense-mediated decay²² nonsense-mediated decay
a cellular quality-control mechanism that degrades mRNA transcripts containing premature stop codons, preventing production of toxic truncated proteins — meaning the mutant allele produces essentially no functional desmoplakin protein. The result is haploinsufficiency: only one functional DSP allele remains to supply desmoplakin to every intercalated disc in every cardiomyocyte, leaving the heart structurally vulnerable.

This variant is classified Pathogenic/Likely pathogenic by 10 major genetic testing laboratories in ClinVar (VCV000044922), including GeneDx, Mayo Clinic Laboratories, Ambry Genetics, Labcorp Genetics, and the Stanford Center for Inherited Cardiovascular Disease — the highest possible evidence tier for rare disease variants.

The Mechanism

The p.Arg160Ter variant sits in the N-terminal head domain of DSP, upstream of the plakin domain and both spectrin repeat rod domains. A stop codon this early in the protein eliminates the entire functional architecture of desmoplakin. Recent experimental work³³ Recent experimental work
Smith et al., bioRxiv 2025 demonstrated that truncating DSP variants reduce DSP protein levels by 23–62% of normal in patient-derived cardiomyocytes. Under conditions of heightened contractile stress (simulated by endothelin-1 exposure), DSP-haploinsufficient cardiomyocytes showed 75% adhesion failure versus only 8% in controls. At baseline contractile load, adhesion was intact — explaining why carriers can appear clinically normal for decades before disease manifests during physiological or pathological stress (intense exercise, myocarditis, pregnancy).

The loss of desmosomal integrity triggers a cascade: cardiomyocytes detach and die, the immune system responds with inflammation, and myofibroblasts replace the lost muscle with fibrous and fatty tissue. This fibrofatty replacement creates late gadolinium enhancement⁴⁴ late gadolinium enhancement
a signal on cardiac MRI that indicates fibrous scar tissue, where gadolinium contrast agent persists because normal cardiomyocytes wash it out but scar tissue cannot visible on cardiac MRI and provides the electrical substrate for reentrant ventricular tachycardia and ventricular fibrillation.

The Evidence

DSP cardiomyopathy is now recognized as a distinct entity from classical arrhythmogenic right ventricular cardiomyopathy (ARVC). The landmark multicenter study by Smith et al., Circulation 2020⁵⁵ multicenter study by Smith et al., Circulation 2020
107 DSP and 81 PKP2 patients established that DSP mutations produce left-dominant disease in 55% of patients (versus 0% for PKP2), with LV late gadolinium enhancement in 40% and acute myocardial injury episodes — a myocarditis-like inflammatory flare — in 15%. Right ventricular cardiomyopathy was present in only 14% of DSP patients, meaning classical ARVC diagnostic criteria systematically miss DSP disease.

The largest outcomes study to date, Gasperetti et al., Eur Heart J 2025⁶⁶ Gasperetti et al., Eur Heart J 2025
800 patients with pathogenic DSP variants across 26 international institutions, found that 17.4% of DSP carriers experienced sustained ventricular arrhythmias (3.9%/year). Myocardial injury episodes — which 8.8% of carriers experienced — dramatically amplified subsequent risk: hazard ratio 2.394 for sustained VA and 5.064 for heart failure hospitalization.

For variants specifically triggering nonsense-mediated decay of both major DSP isoforms⁷⁷ nonsense-mediated decay of both major DSP isoforms
both DSP-I (ubiquitous isoform) and DSP-II (heart-enriched shorter isoform) are eliminated, maximizing the desmoplakin deficit in cardiac tissue — as p.Arg160Ter does — the Hoorntje et al., Circ Genom Precis Med 2023⁸⁸ Hoorntje et al., Circ Genom Precis Med 2023
170 DSP patients from an international cohort study found these individuals were dramatically overrepresented among clinically affected patients versus unaffected carriers (83.6% vs 16.4%, p<0.0001). Ventricular arrhythmia occurred in 33% of affected individuals in this cohort.

Genotype-phenotype analysis confirms that DSP non-missense variants (truncating, frameshift, splice site — all producing haploinsufficiency) carry substantially worse LV involvement than missense variants: LV dysfunction in 76.5% vs 10%⁹⁹ LV dysfunction in 76.5% vs 10% (p=0.001) and LV MRI involvement in 92% vs 22% (p=0.001).

Practical Actions

Carriers of pathogenic DSP variants require cardiomyopathy-specialist care, not routine cardiology follow-up. The standard ARVC Task Force Criteria are specifically less sensitive for DSP disease because they prioritize right ventricular findings — a cardiac MRI protocol looking for subepicardial LV late gadolinium enhancement is the key diagnostic test.

Risk stratification now has a validated clinical tool: the DSP risk score integrates female sex, NSVT history, PVC burden, LVEF, and RV function to stratify 5-year VA risk as low (<5%), intermediate (5–20%), or high (>20%). Patients in the high-risk category should be considered for ICD implantation regardless of whether they have had a documented arrhythmic event. Patients who experience a myocardial injury episode (acute troponin rise with myocarditis- like presentation) should be urgently re-evaluated, as this dramatically escalates risk.

First-degree family members (parents, siblings, children) each carry a 50% risk of inheriting this variant. Cascade genetic testing and cardiac imaging of all adult relatives is standard of care.

Interactions

The R160* variant eliminates both major DSP isoforms (DSP-I and DSP-II) through nonsense-mediated decay — this biallelic isoform impact distinguishes early-truncating variants from variants that spare the heart-enriched DSP-II isoform and may explain the particularly high clinical penetrance observed.

DSP haploinsufficiency can interact with physiological demands that stress desmosomal integrity: intense endurance or resistance exercise, viral myocarditis, and pregnancy have all been associated with acute myocardial injury episodes (inflammatory flares) in DSP cardiomyopathy carriers. These events — detectable by troponin elevation — independently predict subsequent arrhythmia and heart failure and should prompt immediate cardiac evaluation.

Among desmosomal gene variants, double-variant carriers (a pathogenic DSP variant plus a pathogenic variant in PKP2, DSG2, or DSC2) show substantially worse outcomes than single-variant carriers in the desmosomal cardiomyopathy cohort data. If additional desmosomal variants are identified on clinical genetic testing, this escalates management urgency.

Every time your body encounters a bacterium, a first-responder system fires before the adaptive immune response even wakes up. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
TLR2 is a pattern-recognition receptor on the surface of macrophages, monocytes, dendritic cells, and epithelial cells stands at this front line, recognizing bacterial lipoproteins, peptidoglycan, lipoteichoic acid, and mycobacterial components. The R753Q variant (rs5743708), caused by a G-to-A transition at nucleotide 2258, replaces the positively charged arginine with neutral glutamine at position 753 in the receptor's TIR domain²² TIR domain
the Toll/IL-1 receptor domain — the intracellular signaling region that recruits adaptor proteins and initiates the inflammatory cascade. This single amino acid swap disables much of TLR2's capacity to fire.

The R753Q variant is almost exclusively a European polymorphism: approximately 3% of people of European descent carry at least one copy, compared to less than 0.3% in African and East Asian populations. This population specificity makes it a particularly important variant for European-ancestry users.

The Mechanism

The substitution of glutamine for arginine at position 753 changes the electrostatic potential of the DD loop³³ electrostatic potential of the DD loop
a structural element in the TIR domain critical for protein-protein interactions — the precise region where adaptor proteins dock onto TLR2. The consequences cascade through the entire signaling chain: R753Q TLR2 exhibits severely impaired tyrosine phosphorylation⁴⁴ severely impaired tyrosine phosphorylation
4.8-7.5-fold reduction compared to wild-type — a proximal step required for signaling complex assembly, fails to efficiently dimerize with its partner TLR6 (5.9-8-fold reduction), and blocks recruitment of the adaptor proteins MAL and MyD88 that relay the signal to NF-κB.

The end result: where wild-type TLR2 produces 42-fold induction of IL-8 in response to inactivated Mycobacterium tuberculosis components, R753Q TLR2 produces only 4-fold induction⁵⁵ 4-fold induction
even a 100-fold increase in mutant TLR2 expression cannot overcome this deficit. The defect is qualitative, not merely quantitative — the receptor is functionally crippled regardless of how much of it is present. Studies using knock-in mice confirmed that macrophages expressing R753Q show reduced TNF-α, IL-1β, IL-6, and IL-10 production⁶⁶ reduced TNF-α, IL-1β, IL-6, and IL-10 production
along with impaired IRAK-1, p38, ERK1/2, and NF-κB p65 phosphorylation upon mycobacterial challenge.

The Evidence

Tuberculosis is the most extensively studied consequence. A meta-analysis of 19 case-control studies⁷⁷ meta-analysis of 19 case-control studies
4,970 tuberculosis cases and 4,105 controls from Asian and Caucasian populations found that the A allele confers an odds ratio of 2.80 for tuberculosis disease across all genetic models, rising to 5.80 for AA homozygotes. The risk is consistent across both Asian and Caucasian populations, though slightly higher in Asians (OR 3.42 vs 2.39 in Caucasians in the allelic model).

CMV after transplantation shows the most dramatic individual finding. A study of 737 liver transplant recipients⁸⁸ 737 liver transplant recipients
92 patients (12.5%) developed CMV disease within 24 months found that homozygosity for R753Q was associated with a hazard ratio of 3.41 for tissue-invasive CMV disease. This reflects TLR2's documented role in recognizing CMV glycoprotein B — cells expressing R753Q TLR2 show abrogated NF-κB activity when challenged with CMV⁹⁹ abrogated NF-κB activity when challenged with CMV
validating the clinical transplant findings with functional data.

Atopic dermatitis with a severe phenotype clusters in R753Q carriers. The polymorphism defines a distinct subgroup¹⁰¹⁰ defines a distinct subgroup
9 of 78 AD patients (11.5%) were heterozygous for R753Q with median SCORAD scores of 55.8 vs 44.8 in non-carriers, and all carriers had SCORAD above 30 — indicating at least moderate disease. All carriers showed higher total IgE and Dermatophagoides pteronyssinus-specific IgE. A subsequent meta-analysis of nine studies¹¹¹¹ meta-analysis of nine studies
OR 2.07 for atopic dermatitis risk in Caucasians with GA genotype confirmed this association. The mechanism links to impaired IL-8 secretion in response to S. aureus¹²¹² impaired IL-8 secretion in response to S. aureus
which colonizes the skin of nearly all severe AD patients and perpetuates the inflammatory cycle.

Sepsis susceptibility is also elevated. A study using both computational structural modeling and patient data found significant association between TLR2 Arg753Gln and sepsis¹³¹³ significant association between TLR2 Arg753Gln and sepsis
under the over-dominant model, p=0.043, consistent with the expected biology of reduced inflammatory signaling impairing bacterial clearance.

Practical Implications

The picture painted across all these studies is consistent: R753Q carriers mount a blunted initial response when TLR2 ligands are present. This matters most for gram-positive bacteria (which produce the peptidoglycan and lipoproteins TLR2 recognizes), mycobacteria, and certain viruses like CMV. The implications are practical: faster medical attention for infections, optimizing vaccination status, and — for those with atopic dermatitis — recognizing that S. aureus colonization management is especially important.

Lyme disease is a notable exception. Patients with R753Q show significantly lower frequency in severe late-stage Lyme disease¹⁴¹⁴ significantly lower frequency in severe late-stage Lyme disease
possibly due to reduced inflammatory pathology from attenuated TLR2 responses to Borrelia spirochetes, suggesting the dampened immune response can be protective when the disease is primarily driven by immune overactivation rather than pathogen burden.

Interactions

TLR2 does not act alone. It forms heterodimers with TLR1 (recognizing triacylated lipopeptides) and TLR6 (recognizing diacylated lipopeptides and lipoteichoic acid) — and R753Q directly impairs this dimerization. TLR1 rs5743618, a common coding variant, alters TLR1 surface expression and affects combined TLR1/TLR2 signaling; the CGG haplotype (rs5743618–rs5743708–rs5743810 in TLR6) was associated with increased leprosy susceptibility in a Colombian population, suggesting additive effects across the TLR1/2/6 recognition complex.

The CD14 gene (rs2569190)¹⁵¹⁵ CD14 gene (rs2569190)
CD14 encodes the co-receptor that presents bacterial lipopolysaccharide and lipoproteins to TLR2 and TLR4 encodes a co-receptor that delivers bacterial products to TLR2 and TLR4. CD14 variants that reduce its expression would compound TLR2 R753Q impairment, potentially amplifying the signaling deficit further.

For individuals with TLR2 R753Q who also carry TLR4 Asp299Gly (rs4986790), the innate immune system faces a double impairment: blunted gram-positive and mycobacterial recognition (TLR2) alongside reduced gram-negative endotoxin recognition (TLR4). This combined state would warrant heightened infection awareness across a wider pathogen spectrum.

Your liver clears cholesterol from the bloodstream using a receptor called SR-BI, encoded by the SCARB1 gene. SR-BI is the primary docking site where HDL particles offload their cholesterol cargo for processing and excretion in bile — the final step of reverse cholesterol transport¹¹ reverse cholesterol transport
the process by which cholesterol is shuttled from peripheral tissues back to the liver for elimination. When SR-BI expression is reduced, HDL particles circulate longer without fully unloading their cargo, which can impair the liver's ability to process cholesterol and may subtly raise cardiovascular risk.

The rs5888 variant is a synonymous change in exon 8 of SCARB1 — synonymous meaning the amino acid sequence of the protein is unchanged. Yet the variant still matters: not every nucleotide change that preserves an amino acid is functionally neutral.

The Mechanism

Despite producing the same alanine amino acid (Ala350Ala), rs5888 alters the RNA secondary structure of the SCARB1 transcript. The T allele (the A allele on the genomic plus strand) creates a different codon — GCC instead of GCT — that causes the ribosomal machinery to stall. A key in vitro study²² key in vitro study
Constantineau et al. A synonymous variant in scavenger receptor, class B, type I gene is associated with lower SR-BI protein expression and function. Atherosclerosis, 2010 showed that cells expressing the risk variant have significantly lower SR-BI protein levels (p<0.04) and markedly reduced capacity for HDL cholesterol ester uptake (p<0.00001). The transcript levels are identical between genotypes — the difference is purely translational, with more mRNA trapped in non-translating ribosomal pools.

SR-BI also transports dietary carotenoids — particularly lutein and zeaxanthin — to the retinal pigment epithelium, where they form the macular pigment that filters harmful blue light. Impaired SR-BI activity can reduce delivery of these protective pigments to the macula, which may explain the AMD association described below.

The Evidence

A meta-analysis of 12 studies totalling 12,147 subjects³³ meta-analysis of 12 studies totalling 12,147 subjects
Ye et al. Meta-analysis of the association between SCARB1 polymorphism and fasting blood lipid levels. Oncotarget, 2017 found that T-allele carriers (in plus-strand notation: A-allele carriers) had significantly higher HDL-C and lower triglycerides specifically in non-Asian men (SMD 0.15 for HDL-C; p≤0.001). A separate meta-analysis of 7 studies⁴⁴ meta-analysis of 7 studies
Ma et al. SCARB1 rs5888 gene polymorphisms in coronary heart disease: A systematic review and meta-analysis. Gene, 2018 (6,360 subjects) found the T allele associated with reduced coronary heart disease risk in males (OR 0.79; 95% CI 0.61–1.01).

The effects are sex-specific and age-dependent. A Lithuanian population study⁵⁵ A Lithuanian population study
Stanislovaitiene et al. SCARB1 single nucleotide polymorphism (rs5888) is associated with serum lipid profile and myocardial infarction in an age- and gender-dependent manner. Lipids Health Dis, 2013 of 2,439 subjects found that TT homozygous older males (65–74 years) had dramatically reduced MI risk (OR 0.24, 95% CI 0.10–0.56, p=0.001) and higher HDL levels. In young females (25–44 years), TT was associated with lower LDL-C. A smaller Amish cohort⁶⁶ smaller Amish cohort
Roberts et al. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. Hum Hered, 2007 similarly found rs5888 associated with higher HDL-C in women under 50 but not in older women.

A pharmacogenomics study⁷⁷ pharmacogenomics study
Wu et al. Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome. Pharmgenomics Pers Med, 2020 found that female ACS patients carrying the T allele had a greater reduction in LDL-C and ApoB after atorvastatin treatment, suggesting genotype-specific statin responsiveness in women.

AMD and Carotenoid Transport

A case-control study⁸⁸ case-control study
Zerbib et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS One, 2009 in French and North American cohorts found that heterozygotes (CT genotype, i.e. AG in plus-strand notation) had substantially elevated AMD risk (pooled OR 2.9, 95% CI 1.6–5.3) compared to CC homozygotes — specifically among subjects without CFH or ARMS2 risk variants. The proposed mechanism is impaired SR-BI-mediated delivery of lutein and zeaxanthin to the retinal pigment epithelium.

This AMD association has not been replicated in large GWAS studies, so it should be interpreted as an emerging finding rather than established science.

Practical Actions

For the AA genotype (TT on coding strand), which has the lowest estimated SR-BI expression, the most directly actionable steps are dietary: ensuring adequate intake of preformed lutein and zeaxanthin (since SR-BI mediates their retinal delivery) and monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency. For women on statins, the rs5888 genotype may influence treatment response, warranting closer monitoring.

Interactions

The lipid effects of rs5888 interact with those of CETP (rs708272) and LIPC (rs1532085) — genes that also regulate HDL metabolism. Individuals carrying risk alleles at multiple HDL pathway loci may have compounded HDL impairment beyond what rs5888 predicts alone. APOE (rs429358) interacts through a different mechanism: APOE ε4 impairs LDL clearance, and combined APOE4 + reduced SR-BI function could produce both LDL elevation and HDL impairment, though formal interaction studies are limited.

Your circulating vitamin B12 is not simply a readout of how much B12 you eat — it is actively shaped by the proteins that carry B12 in your blood and determine how quickly it is cleared from circulation. The FUT2 gene encodes alpha-(1,2)-fucosyltransferase 2¹¹ alpha-(1,2)-fucosyltransferase 2
An enzyme that adds fucose sugar residues to glycan chains on cell surfaces and on secreted proteins, creating the H blood group antigen on mucosal surfaces and modifying the glycosylation of carrier proteins like haptocorrin, an enzyme that influences B12 metabolism through a specific post-translational modification of haptocorrin — the protein that binds most of the B12 in your blood. The Gly258Ser variant (rs602662) changes a glycine to a serine at amino acid position 258 of the FUT2 protein. People with the G allele (Gly258) carry a form of FUT2 that more actively fucosylates haptocorrin, leading to lower measured serum B12. People with two A alleles (Ser258) have altered enzyme activity, less fucosylation of haptocorrin, and paradoxically higher circulating B12 measurements. This variant is in strong linkage disequilibrium²² linkage disequilibrium
When two SNPs are inherited together so frequently that knowing one predicts the other — in this case r² = 0.76-0.92 in Europeans with rs601338 (the W143X nonsense mutation that determines classical secretor status), but represents an independent missense change with its own protein-level consequences on enzymatic activity.

The Mechanism

FUT2 fucosylates haptocorrin³³ haptocorrin
Also called transcobalamin I or R-binder — a heavily glycosylated protein synthesized mainly by salivary glands and gastric mucosa that binds B12 in the gut to protect it from acid degradation, then releases it in the small intestine. In the bloodstream, haptocorrin carries approximately 70-80% of total serum B12, adding fucose residues to its complex glycan chains. This fucosylation affects how haptocorrin is recognized and cleared by the liver. The asialoglycoprotein receptor⁴⁴ asialoglycoprotein receptor
A lectin receptor on hepatocytes that preferentially binds and internalizes glycoproteins bearing exposed galactose or N-acetylgalactosamine residues — residues that become exposed when the terminal sialic acid is removed. Fucosylation competes with sialylation on these glycan positions, altering which glycoforms predominate (ASGR) on liver cells is responsible for clearing haptocorrin from the bloodstream. The degree of fucosylation alters the rate of this hepatic clearance. In carriers of the G allele (Gly258, higher FUT2 activity), haptocorrin is more thoroughly fucosylated, shifts toward the TCIII glycoform, and is cleared more efficiently from the blood — resulting in lower measured serum B12. In AA individuals (Ser258, lower FUT2 activity on this residue), haptocorrin retains more sialylation, resists ASGR-mediated clearance, and accumulates to higher levels in the bloodstream. Critically, Velkova et al. 2017⁵⁵ Velkova et al. 2017
Velkova A et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin, but not holo-transcobalamin, and is associated with haptocorrin glycosylation. Hum Mol Genet, 2017 demonstrated that these FUT2 variants only affect holo-haptocorrin, not holo-transcobalamin⁶⁶ holo-transcobalamin
The approximately 20-30% of blood B12 bound to transcobalamin II — the only form actively taken up by cells via the TCN2 receptor. Only holoTC reflects the B12 available for cellular use; haptocorrin- bound B12 is not accessible to most cells — the biologically active fraction. This is the critical practical implication: standard serum B12 tests measure total B12 (mostly haptocorrin-bound), and GG individuals with lower total B12 may actually have normal cellular B12 availability, while standard tests can give an artificially low result. Conversely, AA individuals with higher total B12 measurements may have perfectly normal cellular B12 availability.

The Evidence

Two independent GWAS studies identified rs602662 as a top hit for plasma vitamin B12. Tanaka et al. 2009⁷⁷ Tanaka et al. 2009
Tanaka T et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet, 2009 analyzed 3,622 participants in three Italian cohorts and found rs602662 to be the single strongest genetic association with vitamin B12 (p = 2.83 x 10^-20). The combined analysis by Hazra et al. 2008⁸⁸ Hazra et al. 2008
Hazra A et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet, 2008 in 2,717 women identified the FUT2 locus (lead SNP rs492602, in strong LD with rs602662) at p = 5.36 × 10⁻¹⁷, with GG individuals having substantially lower B12 than the AA group. A 2024 study in kidney transplant patients Kotowski et al.⁹⁹ Kotowski et al.
Kotowski M et al. The Importance of the FUT2 rs602662 Polymorphism in the Risk of Cardiovascular Complications in Patients after Kidney Transplantation. Int J Mol Sci, 2024 found that the G allele was present in 65% of hypertensive patients versus 56% of normotensive patients — consistent with the lower B12 leading to higher homocysteine and greater cardiovascular risk. A metabolic study de Luis et al. 2022¹⁰¹⁰ de Luis et al. 2022
de Luis DA et al. Effect of the variant rs602662 of FUT2 gene on anthropometric and metabolic parameters in a Caucasian obese population. Eur Rev Med Pharmacol Sci, 2022 found that AA homozygotes had significantly lower BMI, better lipid profiles, lower fasting glucose, reduced insulin resistance, and a 72% lower metabolic syndrome risk (OR 0.28) compared to GG+GA carriers — an observation that may connect FUT2 biology to wider metabolic regulation.

Practical Implications

The key practical point for GG individuals (and to a lesser extent GA carriers) is awareness: if your standard serum B12 test comes back in the lower-normal range, your result may be influenced by your genotype rather than your dietary intake alone. Requesting a holotranscobalamin¹¹¹¹ holotranscobalamin
Also called "active B12" or holoTC — the B12 fraction bound to transcobalamin II that is available for cellular uptake. Normal range is typically above 35-50 pmol/L test instead of, or alongside, total serum B12 gives a more accurate picture of your functional B12 status. Alternatively, methylmalonic acid (MMA) — which rises specifically when cells lack functional B12 — provides a direct functional readout. For AA individuals, the opposite consideration applies: your total serum B12 may read higher than average, but this primarily reflects haptocorrin-bound B12 in circulation, not improved cellular availability. Standard B12 testing can be misleadingly reassuring if cellular deficiency is a concern.

Interactions

rs602662 is in strong linkage disequilibrium with rs601338 (W143X, the primary European secretor variant) with r² = 0.76-0.92 in Europeans. Together these variants capture FUT2 enzymatic activity from two different positions in the protein — rs601338 causes complete truncation at Trp143, while rs602662 alters activity at Gly258. The associated B12-lowering effects of both variants are mediated through the same haptocorrin glycosylation mechanism, and their effects largely overlap in European populations. For individuals of East Asian ancestry, the classical W143X non-secretor allele (rs601338) is nearly absent. A different FUT2 variant, rs1047781 (A385T, Ile129Phe), is the primary East Asian non-secretor allele. The rs602662 Gly258Ser change is correspondingly rare in East Asian populations, making this variant much less informative in that ancestry context. The downstream effect of lower B12 from GG genotypes intersects with one-carbon metabolism. Vitamin B12 is required for the methionine synthase reaction that converts homocysteine back to methionine. Chronically lower B12 can raise homocysteine, increasing cardiovascular and neurological risk. This interaction is especially relevant in individuals who also carry MTHFR variants (rs1801133 C677T or rs1801131 A1298C) that impair folate-driven remethylation — the two pathways jointly determine homocysteine levels.

Monoamine oxidase A (MAOA) is a mitochondrial enzyme responsible for breaking down neurotransmitters including serotonin, dopamine, norepinephrine, and epinephrine¹¹ serotonin, dopamine, norepinephrine, and epinephrine
These are key chemical messengers that regulate mood, motivation, stress response, and emotional regulation. The rs6323 variant, despite being synonymous (meaning it doesn't change the amino acid sequence at position 297), significantly affects how efficiently this enzyme works. This is a classic example of how ²² DNA changes don't need to alter protein structure to have meaningful biological effects — they can influence gene expression, mRNA stability, or protein folding.

The variant exists in two forms: G, which produces higher MAOA activity, and T, which produces lower activity³³ G, which produces higher MAOA activity, and T, which produces lower activity
The G allele encodes the high-activity form while T encodes the low-activity form. Because MAOA is located on the X chromosome, males (who have only one X) express whichever version they inherit, while females (with two X chromosomes) can have varying combinations. About 29% of Europeans carry the T (lower activity) allele, with higher frequencies in East Asian populations (~48%).

The Mechanism

MAOA requires flavin adenine dinucleotide (FAD) as a covalently attached cofactor⁴⁴ flavin adenine dinucleotide (FAD) as a covalently attached cofactor
FAD is derived from riboflavin (vitamin B2) and is permanently bound to the MAOA enzyme. The R297R variant affects enzyme activity through mechanisms that remain incompletely understood but likely involve mRNA stability or protein folding efficiency rather than direct catalytic changes. Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele⁵⁵ Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele
This translates to faster breakdown of monoamine neurotransmitters.

Lower MAOA activity (T allele) leads to slower breakdown of serotonin, dopamine, and norepinephrine, resulting in higher baseline levels of these neurotransmitters. Conversely, higher activity (G allele) means faster degradation and potentially lower neurotransmitter availability, though the body often compensates through feedback mechanisms and altered receptor sensitivity⁶⁶ feedback mechanisms and altered receptor sensitivity
The relationship between MAOA activity and mood is complex and influenced by environmental factors.

The Evidence

The rs6323 variant has been extensively studied in psychiatric and behavioral contexts. A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response⁷⁷ A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response
PMID: 19593178. This suggests they may be less responsive to psychological interventions alone.

In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31⁸⁸ In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31
PMID: 29782859. Park et al., 2018. Journal of Korean Medical Science. However, results vary by sex and population, with some studies showing opposite effects in males versus females.

Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity⁹⁹ Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity
The gene-environment interaction is crucial — the variant alone doesn't determine behavior. The so-called "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies¹⁰¹⁰ "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies
The variant contributes to behavioral tendencies but doesn't determine outcomes.

Evidence level is strong based on consistent replication across multiple populations, though effect sizes are generally modest and highly context-dependent.

Practical Implications

For those with lower MAOA activity (T allele carriers), higher baseline neurotransmitter levels can manifest as emotional intensity, stress sensitivity, or difficulty with emotional regulation. Riboflavin is essential for MAOA function as the precursor to FAD¹¹¹¹ Riboflavin is essential for MAOA function as the precursor to FAD
Adequate B2 status supports optimal enzyme activity. Some individuals with slow MAOA variants report benefits from riboflavin supplementation (100-400 mg daily)¹²¹² riboflavin supplementation (100-400 mg daily)
This supports FAD synthesis and may help normalize enzyme activity.

MAOA activity naturally increases with age and in response to oxidative stress¹³¹³ MAOA activity naturally increases with age and in response to oxidative stress
This means someone with genetically low activity might find symptoms moderate over time. Higher activity variants (G allele) may benefit from ensuring adequate precursors for neurotransmitter synthesis.

For treatment response, antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice¹⁴¹⁴ antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice
SSRIs work by different mechanisms than MAO inhibitors and may have variable effectiveness. MAO inhibitors are typically reserved for treatment-resistant depression.

Interactions

rs6323 interacts with rs1137070, another functional MAOA variant¹⁵¹⁵ rs1137070, another functional MAOA variant
Together these define MAOA haplotypes with different activity levels. The uVNTR (variable number tandem repeat) in the MAOA promoter is perhaps the most well-known MAOA variant and works in combination with rs6323 to determine overall enzyme activity. Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity¹⁶¹⁶ Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity
This may increase susceptibility to mood and behavioral regulation challenges.

MAOA activity also influences the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine¹⁷¹⁷ the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine
Low MAOA activity can increase sensitivity to tyramine and risk of hypertensive reactions when combined with MAO-inhibiting medications.

Neuroserpin¹¹ Neuroserpin
encoded by SERPINI1 on chromosome 3q26 is a serine protease inhibitor expressed primarily in neurons. Its principal job is to regulate tissue-type plasminogen activator (tPA)²² tissue-type plasminogen activator (tPA)
the enzyme that dissolves blood clots in the brain but can also damage the blood-brain barrier when unchecked. The rs6797312 variant sits in intron 1 of SERPINI1 and does not change the protein directly, but may influence how much neuroserpin the brain produces or when it is expressed. A single case-control study identified the A allele as a risk factor for early-onset ischemic stroke among Caucasian women, while a subsequent European replication study found no association — leaving the evidence at the emerging level.

The Mechanism

When ischemia occurs, tPA activity in the brain rises sharply. Unchecked tPA degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)³³ degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)
both of which increase blood-brain barrier permeability and allow inflammatory cells to flood ischemic tissue. Neuroserpin counteracts this by binding and inhibiting tPA within the central nervous system — a role separate from plasminogen activator inhibitor-1 (PAI-1), which controls tPA systemically. Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage⁴⁴ Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage
demonstrating that neuroserpin is the brain's primary tPA gatekeeper. It also maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall⁵⁵ maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall
an anti-inflammatory action separate from its antiprotease role. The intronic rs6797312 variant may reduce neuroserpin expression in a context- or ancestry-specific way, subtly weakening this brain-protective circuit.

The Evidence

The primary association evidence comes from the Stroke Prevention in Young Women (SPYW) study⁶⁶ Stroke Prevention in Young Women (SPYW) study
a population-based case-control study in Maryland and Washington DC, USA by Cole et al. (2007). The study enrolled 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls⁷⁷ 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls
approximately half of each group were African-American. Among Caucasian women, A allele carriers (genotypes AA and AT combined) had a twofold increased odds of stroke compared to TT carriers⁸⁸ twofold increased odds of stroke compared to TT carriers
OR 2.05, 95% CI not reported; p = 0.023, dominant model. No significant association was found in African-American participants (OR 0.71, p = 0.387), a pattern that may reflect different haplotype backgrounds, linkage disequilibrium structure, or allele frequency differences across ancestries (African A allele frequency ~0.39 vs European ~0.59).

A critical counterpoint: Tjärnlund-Wolf et al. (2011)⁹⁹ Tjärnlund-Wolf et al. (2011)
a Swedish cohort including all subtypes of ischemic stroke examined SERPINI1 genetic variation and found no evidence of association with ischemic stroke¹⁰¹⁰ no evidence of association with ischemic stroke
published as a letter to the Journal of Neurology. The non-replication may reflect differences in stroke subtype composition, sex distribution, age range, or simply limited statistical power in the smaller letter-format study. These conflicting results mean rs6797312's role in stroke risk remains plausible but unconfirmed pending larger, ancestry-stratified studies.

Supporting the biological plausibility: clinical studies show that lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown¹¹¹¹ lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown
suggesting that impaired neuroserpin function worsens acute stroke injury.

Practical Actions

Given the emerging and ancestry-specific nature of this evidence, rs6797312 is best understood as a candidate risk modifier rather than an established risk factor. For women of European ancestry, particularly those with additional conventional stroke risk factors, this variant may warrant consideration in overall risk stratification. The most actionable response is awareness of conventional modifiable stroke risk factors — atrial fibrillation, hypertension, migraine with aura, and oral contraceptive use in the context of other risk factors — because these interact with heritable cerebrovascular vulnerabilities. There are no neuroserpin-specific therapies available for clinical use; ongoing research into neuroserpin-delivering extracellular vesicles and recombinant neuroserpin as stroke neuroprotectants is experimental only.

Interactions

Neuroserpin operates in the same fibrinolytic pathway as PAI-1 (SERPINE1, rs1799889) and tPA (PLAT). Variants that alter PAI-1 activity could compound with reduced neuroserpin activity — for example, a PAI-1 4G/5G promoter variant reducing systemic fibrinolysis combined with reduced neuroserpin CNS protection might stack stroke risk through complementary mechanisms. Formal compound-genotype studies have not been conducted. The rs6797312 signal in young women raises the possibility of a sex-hormone-mediated interaction, as estrogen modulates both tPA expression and neuroserpin activity in neurons, but this has not been directly tested in genetic association studies.

Circulating vascular endothelial growth factor A (VEGFA) levels are among the most heritable quantitative traits in the human genome, with genetic architecture spanning multiple loci. The primary genetic determinant of circulating VEGF levels maps to the 6p21.1 region near the VEGFA gene — but GWAS studies of varicose veins, venous thromboembolism, and circulating VEGF concentrations have identified co-segregating signals at neighboring chromosomal regions. rs7030781¹¹ rs7030781
located at chr9:2,686,273 (GRCh38), a non-coding transcript variant in the uncharacterized lncRNA LOC105375957; no direct ClinVar entries or independent GWAS hits as of 2025 is one such regional co-variant that has been identified in relation to VEGFA-pathway phenotypes.

VEGFA drives angiogenesis — the growth of new blood vessels — as well as vascular permeability, endothelial cell survival, and smooth muscle phenotypic switching. Its expression is tightly regulated at the transcriptional and post-transcriptional level by a complex network of promoter elements, enhancers, and non-coding RNAs. Variants that modulate VEGFA expression — whether directly in the VEGFA promoter or through distal regulatory elements and lncRNA-mediated mechanisms — have downstream effects on collateral vessel development after ischemia, venous wall integrity, and endothelial inflammatory responses.

The Mechanism

The rs7030781 T allele maps to an intronic region of LOC105375957, an uncharacterized long non-coding RNA on chromosome 9. While the precise functional mechanism has not been established experimentally, lncRNAs in this class are known to regulate gene expression through chromatin remodeling, RNA-binding protein interactions, and transcriptional co-activation. A fraction of chr9 lncRNA variants have documented eQTL²² eQTL
expression quantitative trait locus: a genomic position where variation predicts expression level of a nearby or distant gene effects on vascular gene expression in endothelial and smooth muscle tissues.

The A/T variant at rs7030781 is an ambiguous SNP³³ ambiguous SNP
the complement of A is T and T is A — a strand-orientation ambiguity requiring careful population frequency verification to confirm which allele is reference and which is risk. The GRCh38 plus-strand reference allele is A; the T allele is the globally more prevalent alternate allele in large sequencing cohorts (TOPMED: T=53.5%, 1000 Genomes: T=57%), though notably less common in European populations (ALFA European: T=27%). This ancestry-specific frequency variation may reflect different selective pressures on vascular regulatory architecture across populations.

The Evidence

The evidence for rs7030781 as an independent functional variant is currently emerging⁴⁴ emerging
one or zero studies with small or no direct functional data. Its biological relevance is inferred from:

1. Regional co-segregation: rs7030781 was identified as a co-variant in VEGFA-pathway analyses — most notably the largest varicose vein GWAS to date⁵⁵ largest varicose vein GWAS to date
   135,514 cases and 675,111 controls across UK Biobank and 23andMe cohorts, identifying 49 genome-wide significant loci — through regional tagging of the 6p21.1 VEGFA neighborhood and correlated chromosomal architectures.

2. Circulating VEGF level instruments: Ahola-Olli et al. 2017⁶⁶ Ahola-Olli et al. 2017
   GWAS of 41 circulating cytokines and growth factors in 8,293 Finnish participants, identifying 27 genome-wide significant loci mapped rs6921438 as the primary VEGFA instrument. Regional co-variants including chromosome 9 loci have been tagged in related analyses, though rs7030781 itself has not been independently reported as genome-wide significant for any phenotype in the GWAS Catalog as of 2025.

3. Mendelian randomization context: A two-sample MR study⁷⁷ two-sample MR study
   9 VEGF-level instruments analyzed across ~16,000 European participants found that genetically elevated VEGF levels associate with increased venous thromboembolism risk (OR 1.064, 95% CI 1.009–1.122, p=0.022), establishing a causal role for VEGF dysregulation in venous disease. Variants that modulate VEGF pathway activity — including regional co-variants — are relevant to this biological mechanism even when their individual effect sizes fall below genome-wide significance thresholds.

The honest assessment is that rs7030781 has emerging and uncertain evidence. It was included in the GeneOps database as a companion to the stronger VEGFA locus signal at rs11967262, not as an independently replicated risk variant. Its value lies in contributing to a polygenic picture of VEGFA-pathway regulation rather than standing alone as a primary clinical marker.

Practical Actions

Given the limited independent evidence, the main value of knowing your rs7030781 genotype lies in contributing to a multi-variant VEGFA-pathway picture alongside rs11967262 and rs2010963. Carriers of the T allele who also carry risk alleles at those loci may have compounded VEGFA regulatory burden.

The VEGFA pathway is modifiable through specific nutritional and lifestyle levers. VEGFA expression is upregulated by hypoxia (via HIF-1α), inflammation (via NF-κB and TNF-α), and mechanical venous stress. Keeping venous hydrostatic pressure low, reducing chronic low-grade inflammation, and avoiding sustained lower-limb venous stasis all directly modulate the environmental inputs that drive VEGFA dysregulation at these loci.

Interactions

rs7030781 is most meaningfully interpreted alongside rs11967262 (VEGFA upstream regulatory variant, chr6) and rs2010963 (VEGFA 5′-UTR variant). Individuals carrying T alleles at rs7030781 and G alleles at rs11967262 may carry compounded VEGFA-pathway risk. The VEGFA locus also interacts with thrombophilia variants (Factor V Leiden rs6025, Prothrombin rs1799963) — elevated VEGFA increases vascular permeability in a way that amplifies thrombotic risk in the venous circulation.

Regarding circulating VEGF levels: the rs6921438 locus on chromosome 6 is the strongest genetic instrument for VEGF concentrations, and individuals carrying A alleles at rs6921438 have lower circulating VEGF. The chr9 co-variant rs7030781 is thought to operate through a separate but potentially synergistic regulatory mechanism.

SH2B1 (SH2B Adaptor Protein 1) is not a hormone or a receptor — it is the adaptor protein¹¹ adaptor protein
Scaffold proteins that assemble multi-protein signaling complexes at specific cellular locations that turns up the volume on two of the body's most important weight-control signals: leptin and insulin. When SH2B1 works properly, it binds to activated JAK2²² JAK2
Janus Kinase 2 — the intracellular enzyme activated when leptin binds its receptor on hypothalamic neurons, dramatically amplifying its catalytic activity and extending downstream signaling through STAT3³³ STAT3
Signal Transducer and Activator of Transcription 3 — the transcription factor that mediates leptin's appetite-suppressing gene expression program and the PI3-kinase pathway. The rs7498665 variant introduces a single amino acid change that appears to blunt this amplification, particularly in leptin signaling.

The GIANT consortium GWAS⁴⁴ GIANT consortium GWAS
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 identified the SH2B1 locus as one of 18 new genome-wide significant loci for BMI — notable because it sits alongside FTO, MC4R, POMC, and BDNF as one of the few obesity loci that maps directly to a known hypothalamic regulator of energy balance.

The Mechanism

The Thr484Ala substitution falls in the linker region between SH2B1's two key structural domains: the pleckstrin homology (PH) domain⁵⁵ pleckstrin homology (PH) domain
Binds inactive JAK2; positions SH2B1 at the receptor complex before leptin signaling begins (residues 249-378) and the SH2 domain⁶⁶ SH2 domain
Binds phosphorylated, active JAK2; required for full JAK2 activation and downstream signaling (residues 521-625). Position 484 is thus a structural hinge. The ancestral threonine is a polar, hydroxyl-bearing amino acid; the Ala484 substitution removes this polar group, potentially altering how the two domains orient relative to each other and how efficiently SH2B1 transitions from its inactive to active conformation.

Functional evidence confirms the signaling impact is real but leptin-selective. Experiments in hypothalamic cell lines⁷⁷ Experiments in hypothalamic cell lines
Giuranna et al. The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus. Obesity Facts, 2018 showed that SH2B1 variants collectively altered expression of 34 of 54 analyzed leptin signaling genes, with the 484Ala form among the most impactful. Notably, insulin signaling was unaffected, leading the authors to conclude that "leptin rather than insulin signaling is relevant for the mode of action of SH2B1 variants on energy homeostasis." Mice lacking SH2B1 entirely develop severe hyperleptinemia, obesity, and type 2 diabetes — confirming the gene's essential role.

The Evidence

The Thr484Ala variant has been replicated across multiple independent populations. A Belgian case-control study⁸⁸ Belgian case-control study
Beckers et al. Replication of the SH2B1 rs7498665 association with obesity in a Belgian study population. Obesity Facts, 2011 of 1,045 obese adults and 317 lean controls confirmed the G allele increased obesity risk (OR 1.26, 95% CI 1.04-1.52, p=0.016). Japanese CT imaging data revealed the risk allele was significantly associated with visceral fat area⁹⁹ significantly associated with visceral fat area
Hotta et al. SH2B1 rs7498665 and visceral fat area in Japanese adults. Journal of Human Genetics, 2011 (P=0.00047) but not with overall BMI or subcutaneous fat, suggesting a depot-specific effect — the G allele drives abdominal fat accumulation selectively.

Beyond obesity, a study of 18,014 middle-aged Danes¹⁰¹⁰ 18,014 middle-aged Danes
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011 found the G allele independently increased type 2 diabetes risk even after adjusting for BMI (OR 1.16, p=7.8×10⁻⁴). This BMI-independent diabetes association points to a direct metabolic role for SH2B1 beyond its weight-regulatory function — consistent with SH2B1's role in insulin receptor signaling.

Gene-environment interactions are particularly striking. A 2024 study found that GG homozygotes with elevated fasting glucose¹¹¹¹ GG homozygotes with elevated fasting glucose
Chermon et al. Gene-Environment Interactions Significantly Alter the Obesity Risk of SH2B1 rs7498665 Carriers. Journal of Obesity & Metabolic Syndrome, 2024 (≥90 mg/dL) faced 5.82-fold elevated risk of overweight/obesity — while physical activity (≥150 min/week) reduced GG carriers' obesity risk by 65%.

Practical Actions

Because SH2B1 is the amplifier for leptin's satiety signal, strategies that enhance leptin sensitivity are specifically relevant for G allele carriers. High-protein meals trigger satiety hormones (GLP-1, PYY, CCK) via gut receptors that bypass SH2B1-dependent hypothalamic signaling, providing an alternative brake on appetite. The visceral fat–specific association means that measuring waist circumference, not just weight or BMI, gives a more accurate picture of metabolic risk for this genotype.

The fasting glucose interaction is actionable: keeping fasting glucose below 90 mg/dL substantially modifies risk for GG carriers. This threshold is below the standard prediabetes cutoff (100 mg/dL), making periodic fasting glucose testing an important early warning tool.

Interactions

SH2B1 sits directly upstream of the same leptin-JAK2-STAT3 pathway affected by LEPR (rs1137101). Carrying the G risk allele here while also carrying the G risk allele at LEPR rs1137101 compounds impairment at two consecutive steps in leptin signaling: SH2B1 fails to amplify JAK2, and the receptor itself may respond less efficiently to leptin. The cumulative effect on satiety signaling is greater than either variant alone.

rs7498665 also interacts additively with the major obesity GWAS loci FTO (rs9939609) and MC4R (rs17782313) — each variant contributes an independent BMI increment, and carriers of risk alleles at multiple loci face substantially higher cumulative obesity susceptibility. The IRS1 variant rs2943641 affects the insulin receptor substrate arm of SH2B1 signaling; co-occurrence may compound insulin sensitivity effects.

When researchers published the first genome-wide association study to identify IL23R as an inflammatory bowel disease gene in 2006, rs7517847 was the single most significant marker in the entire locus¹¹ single most significant marker in the entire locus
P=3.36×10−13 in the combined analysis of both ileal CD case-control cohorts in Duerr et al. Science 2006 — the landmark study that opened the modern era of IBD genetics. That study found the less common G allele was dramatically less frequent in Crohn's disease patients than in healthy controls (33% vs. 44%), establishing the T allele as the risk variant and the G allele as protective. The variant sits in an intron of IL23R²² IL23R
the gene encoding the IL-23-specific subunit of the heterodimeric IL-23 receptor complex on chromosome 1p31.3, which together with IL12RB1/IL-12Rβ1 forms the complete receptor for the Th17-polarizing cytokine IL-23, the receptor for a cytokine that drives Th17 cell expansion and sustains the inflammatory cascades underlying Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriasis.

Crucially, rs7517847 operates in a distinct linkage disequilibrium block³³ linkage disequilibrium block
LD blocks are chromosomal regions where nearby variants tend to be inherited together; low LD between two variants means they are statistically and biologically independent signals from the other shipped IL23R variant, rs2201841 (r²=0.03 between the two). They are independent signals capturing different aspects of IL23R genetic architecture within the same locus.

The Mechanism

IL23R encodes the IL-23-specific receptor subunit that, together with the shared IL-12Rβ1 subunit, forms the complete IL-23 receptor complex. Upon IL-23 binding, the receptor activates JAK2 and TYK2, which phosphorylate STAT3 and STAT4, driving expression of RORγt — the master transcription factor for Th17 cell differentiation. Sustained Th17 expansion underlies the epithelial damage in IBD, joint inflammation in ankylosing spondylitis, and keratinocyte hyperproliferation in psoriasis.

rs7517847 is an intronic variant that does not change the IL-23 receptor protein sequence. Its mechanism is regulatory⁴⁴ regulatory
intronic variants can influence splicing efficiency, mRNA stability, transcription factor binding within intronic enhancers, or alternative isoform ratios — any of which could subtly modulate receptor surface density or signaling output. The G allele is associated with reduced IL-23 pathway activation, parallel in direction (though independent in mechanism) to the well-characterized protective missense variant rs11209026 (R381Q), which directly reduces receptor surface expression. rs7517847 represents a second, distinct molecular entry point to damping the same IL-23/Th17 axis.

The T allele is the ancestral common form (~59% globally) and represents baseline or slightly elevated pathway activity. Homozygous T carriers do not have an overactive receptor — rather, GG carriers appear to have a slightly reduced set point for IL-23 signaling that confers population-level protection against Th17-driven inflammatory diseases, especially in people of European ancestry.

The Evidence

The foundational study by Duerr et al. published in Science in 2006⁵⁵ foundational study by Duerr et al. published in Science in 2006
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, Science 2006 genotyped 297 individuals with ileal Crohn's disease and 148 controls, then replicated in a second cohort, and found rs7517847 to be the most strongly associated IL23R marker (P=3.36×10−13). The G allele frequency was 0.443 in controls and only 0.331 in CD cases, giving an odds ratio of 0.62 for the protective G allele.

A meta-analysis of 25 studies (9,297 CD cases, 12,643 controls)⁶⁶ meta-analysis of 25 studies (9,297 CD cases, 12,643 controls)
Du et al. Scientific Reports 2015 confirmed robust protection: G allele OR=0.699 (95% CI 0.659–0.741, P<0.001) overall, with the Caucasian-specific effect even stronger (OR=0.669). No significant protective effect was seen in Asian or African populations, making this a Caucasian-predominant signal. A complementary meta-analysis of 11 Caucasian studies⁷⁷ meta-analysis of 11 Caucasian studies
Zhang et al. 2015 framing the T allele as the risk factor found TT vs GG homozygote comparison OR=1.890 (95% CI 1.465–2.437) and dominant model OR=1.652 (95% CI 1.277–2.137) for T risk-allele carriers.

For ankylosing spondylitis, a meta-analysis of 4 studies (1,006 AS cases, 1,190 controls)⁸⁸ ankylosing spondylitis, a meta-analysis of 4 studies (1,006 AS cases, 1,190 controls)
Xu et al. PeerJ 2015 found G allele protective OR=0.88 (95% CI 0.78–0.99, P=0.032) and GG vs TT OR=0.76 (P=0.038). The authors concluded that it was the rs7517847 polymorphism rather than rs2201841 that held the primary statistical association with AS. A separate meta-analysis of 12 UC studies (3,589 cases, 5,536 controls)⁹⁹ meta-analysis of 12 UC studies (3,589 cases, 5,536 controls)
Ye et al. 2017 showed G allele protective OR=0.818 (95% CI 0.768–0.871, P<0.001) in Caucasian populations.

The consistency across CD, UC, and AS — each independently replicated — establishes rs7517847 as one of the best-validated non-HLA susceptibility loci for the cluster of IL-23-driven inflammatory diseases.

Practical Implications

For GG carriers, the genetic data indicate a meaningful reduction in susceptibility to Crohn's disease, ulcerative colitis, and ankylosing spondylitis compared to TT carriers, particularly in people of European ancestry. This is a fortunate genotype from an inflammatory disease perspective — but it does not confer immunity, and other genetic and environmental factors still contribute substantially to disease risk.

For TT carriers — the most common genotype (~35% of Europeans) — the elevated risk is real but modest at the individual level. Most TT carriers will never develop Crohn's disease or AS. However, awareness of symptom patterns that suggest early IBD or spondyloarthritis is valuable, since early diagnosis and treatment dramatically improves long-term outcomes in both conditions. The IL-23/Th17 pathway is directly targeted by multiple approved biologics (ustekinumab, risankizumab, guselkumab for IBD and psoriatic disease; secukinumab, ixekizumab for AS), meaning that if inflammatory disease does develop, effective targeted therapies exist.

Note that this variant's protection is predominantly demonstrated in European populations. People of East Asian or African ancestry should interpret GG genotype with more caution, as the population-stratified meta-analyses showed no significant protective signal in these groups — possibly because the T allele frequency is already very high in some Asian populations, limiting the statistical power to detect differences.

Interactions

rs7517847 and rs2201841 are both intronic IL23R variants associated with overlapping disease spectra but tag independent LD blocks (r²=0.03). Carriers who are TT at rs7517847 (risk) and GG at rs2201841 (risk) face elevated susceptibility from both independent signals — the two variants capture distinct aspects of IL23R regulation within the same gene. Conversely, carrying the protective G allele at rs7517847 alongside the protective A allele at rs2201841 may provide additive dampening of IL-23 pathway activity.

The other major IL23R protective variant, rs11209026 (R381Q/Arg381Gln), acts through a different mechanism — directly reducing receptor surface expression — and is in very low LD with rs7517847 (r²=0.03). The three IL23R signals (rs7517847, rs2201841, rs11209026) each independently tag the same biological pathway through distinct molecular entry points.

For Crohn's disease specifically, documented gene-gene interactions between IL23R variants and NOD2/CARD15 variants (rs2066844, rs2066845) suggest that TT carriers who also carry NOD2 risk alleles face a substantially amplified IBD risk. The rs7517847 × NOD2 interaction has not been quantified directly but is biologically plausible given the established IL23R × NOD2 interaction reported for rs2201841.

Most vitamin D research focuses on the four classic loci — the skin synthesis enzyme DHCR7, the liver hydroxylase CYP2R1, the transport protein GC, and the catabolic enzyme CYP24A1. In 2018, a large genome-wide association study added two new players to this network, one of which sits in an unexpected place: a gene encoding a structural component of the cell's internal postal system rather than a dedicated vitamin D enzyme.

SEC23A¹¹ SEC23A
SEC23 homolog A, a component of the COPII coat complex that mediates the first step of the secretory pathway — packaging newly synthesized proteins into vesicles that bud off the endoplasmic reticulum and travel to the Golgi apparatus is a core component of the COPII coat complex²² COPII coat complex
Coat Protein complex II; a set of five proteins (SAR1, SEC23, SEC24, SEC13, SEC31) that polymerize around ER membranes to form transport vesicles carrying newly made secretory and membrane proteins toward the Golgi and ultimately to their final destinations — including the cell surface and the bloodstream, the protein machinery responsible for shipping newly synthesized proteins from the endoplasmic reticulum to the Golgi apparatus. The rs8018720 variant changes a single amino acid in SEC23A (leucine to valine at position 211), and carriers of the minor G allele show measurably higher circulating 25-hydroxyvitamin D concentrations.

The Mechanism

The precise molecular mechanism remains incompletely understood, which is why this variant carries an emerging evidence grade. However, the biological plausibility is straightforward: several proteins central to vitamin D metabolism are secreted proteins that transit the ER-Golgi pathway. The most prominent candidate is GC-globulin³³ GC-globulin
Also called vitamin D binding protein (VDBP or DBP); a liver-derived plasma protein that carries approximately 85–90% of circulating 25(OH)D. GC must pass through the COPII pathway to be secreted into the bloodstream (vitamin D binding protein, encoded by the GC gene), a liver-synthesized protein that carries approximately 85–90% of circulating 25(OH)D in the bloodstream. If the Leu211Val substitution in SEC23A alters the efficiency or cargo selectivity of COPII vesicle formation, it could change how much GC — and therefore how much vitamin D — is delivered to circulation.

Similarly, the 25-hydroxylase CYP2R1⁴⁴ 25-hydroxylase CYP2R1
The predominant liver enzyme responsible for the first activation step of vitamin D: converting cholecalciferol (D3) to 25-hydroxyvitamin D (calcidiol), the major circulating form measured in blood tests is an ER-resident enzyme whose substrate and product must transit the secretory pathway; any change in ER membrane dynamics or vesicle budding could influence this process. The Leu211 position is within a functional domain of SEC23A involved in GTPase activation of SAR1 (the molecular switch that triggers COPII assembly), making it structurally plausible that the Val substitution modestly alters COPII efficiency.

The Evidence

The discovery GWAS by Jiang and colleagues⁵⁵ discovery GWAS by Jiang and colleagues
Jiang X et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nat Commun, 2018 expanded an earlier discovery sample from 16,125 to 79,366 European-ancestry individuals and identified rs8018720 at genome-wide significance (P = 4.7×10⁻⁹). This brought the total number of confirmed vitamin D loci from four to six. The G allele, carried by approximately 17% of Europeans, was associated with higher circulating 25(OH)D concentrations. The study also found that vitamin D genetic signals cluster preferentially in immune and hematopoietic tissues, consistent with vitamin D's broad immunomodulatory role.

Beyond the discovery study, rs8018720 has been incorporated into vitamin D genetic risk scores (GRS) used in Mendelian randomization analyses. A study of Barrett's esophagus and esophageal adenocarcinoma⁶⁶ study of Barrett's esophagus and esophageal adenocarcinoma
Dong J et al. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clin Gastroenterol Hepatol, 2019 included this variant among six SNPs in a GRS involving 6,167 cases and 17,159 controls, finding no causal effect. A meta-analysis of genetic evidence for vitamin D and type 1 diabetes⁷⁷ meta-analysis of genetic evidence for vitamin D and type 1 diabetes
Najjar L et al. Nutrients, 2021 similarly found no pooled association (OR 0.97–1.02) with seven vitamin D SNPs including rs8018720 — an informative null result showing the vitamin D effect is not large enough to drive T1D risk through this variant alone.

A 2022 autoimmune study⁸⁸ 2022 autoimmune study
Vanderlinden LA et al. Frontiers in Immunology, 2022 found that the C allele at rs8018720 was associated with rheumatoid arthritis autoantibodies among first-degree relatives of RA/SLE probands (OR = 0.65, 95% CI 0.43–0.99), suggesting a modest immunological signal consistent with the known role of vitamin D in autoimmune regulation.

It is important to calibrate expectations: the effect size at this locus is small. The per-allele change in 25(OH)D is likely in the range of 1–3 nmol/L, smaller than the major loci (GC, CYP2R1, DHCR7, CYP24A1). The variant's clinical relevance is primarily as a contributor to cumulative genetic risk rather than as a stand-alone determinant of vitamin D status.

Practical Actions

The C allele at rs8018720 is the common form in most populations (~82% globally). Most people carry CC and have vitamin D levels reflecting typical SEC23A function. Carriers of the G allele (CG or GG) have a mild genetic tendency toward higher circulating 25(OH)D, which may provide a slight buffer against vitamin D insufficiency.

Because the effect size is modest and the mechanism is unproven, this variant should be interpreted as one data point in a broader vitamin D status picture. Blood testing remains the most important tool for individual vitamin D management. Supplementation with cholecalciferol (D3) bypasses the upstream synthesis and transport processes entirely, making it an effective intervention regardless of this genotype.

Interactions

SEC23A's proposed mechanism — influencing the secretory efficiency of GC-globulin (vitamin D binding protein) — means it may interact most meaningfully with variants in the GC gene itself (rs7041, rs4588). If SEC23A is secreting GC less efficiently AND that GC has altered vitamin D binding properties, the combined effect could be more pronounced than either variant alone. CYP2R1 (rs10741657, rs6994076) and CYP24A1 (rs6013897) remain the highest-impact partners for vitamin D pathway interactions. The GWAS that discovered rs8018720 also identified AMDHD1 (rs10745742) as a second novel locus in the same study.